公开(公告)号：US20240358795A1

公开(公告)日：2024-10-31

申请号：US18767040

申请日：2024-07-09

申请人： UNIVERSITE D'AIX-MARSEILLE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

发明人： FRANCESCA NADÈGE JOËLLE ROCHAIS

IPC分类号： A61K38/18

CPC分类号： A61K38/1825

摘要： The present invention relates to the activation of FGF10 signaling pathway for use in the treatment of a heart disease.

公开(公告)号：US20240350508A1

公开(公告)日：2024-10-24

申请号：US18683083

申请日：2022-08-24

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN ,  UNIVERSITÉ DE ROUEN NORMANDIE

发明人： Sylvain FRAINEAU ,  Nicolas PERZO

IPC分类号： A61K31/5377 ,  A61F2/24 ,  A61K31/496 ,  A61P9/10

CPC分类号： A61K31/5377 ,  A61F2/24 ,  A61K31/496 ,  A61P9/10 ,  A61F2250/0067

摘要： Aortic valve stenosis (AS) also called also called Calcific aortic valve disease (CAVD), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure development and eventually to death within 2 to 5 years after symptoms occurrence. The inventors now show that EZH2 inhibition with GSK-126 and GSK-343 directly regulates monocyte and M1 toward M2 macrophage differentiation, reducing VIC deactivation and osteoblastic transition and thus represents an attractive therapeutic target to prevent AS progression. Therefore, the present invention relates to use of EZH2 inhibitors for the treatment of aortic valve stenosis.

公开(公告)号：US20240302384A1

公开(公告)日：2024-09-12

申请号：US18547759

申请日：2022-03-03

申请人： APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ) ,  UNIVERSITE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ) ,  IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

发明人： Yoram BOUHNIK ,  Alexandre NUZZO ,  Olivier CORCOS ,  Marc-Emmanuel DUMAS ,  Antonis MYRIDAKIS ,  Dominique GAUGUIER

IPC分类号： G01N33/68 ,  G01N33/53 ,  G01N33/92

CPC分类号： G01N33/6893 ,  G01N33/5308 ,  G01N33/92 ,  G01N2570/00 ,  G01N2800/06 ,  G01N2800/7019

摘要： A metabolomic signature of acute mesenteric ischemia (AMI) and the determination thereof in a method for identifying a subject suffering or being at risk of suffering from AMI. Also, a kit that includes elements for determining the metabolomic signature of AMI and implementing the method for identifying a subject suffering or being at risk of suffering from AMI.

公开(公告)号：US20240301497A1

公开(公告)日：2024-09-12

申请号：US17769474

申请日：2020-10-16

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE LORRAINE ,  CENTRE HOSPITALIER ET UNIVERSITAIRE DE NANCY (CHU)

发明人： Rémi HOULGATTE ,  Abderrahim OUSSALAH ,  Jean-Louis GUEANT ,  Patrice GALLET ,  Roger JANKOWSKI

IPC分类号： C12Q1/6886 ,  A61B10/02

CPC分类号： C12Q1/6886 ,  A61B10/02 ,  A61B2010/0216 ,  C12Q2600/154 ,  C12Q2600/158

摘要： The present invention relates to methods and compositions for the diagnostic and for the treatment of nasal intestinal type adenocarcinomas (ITAC). The inventors used a non-invasive brushing technique, which permits to identify transcriptomic and methylation modifications that are consistent with phenotypic profiles and ITACs natural history. Thus, they identified CACNA1C as a new predictive marker of ITAC. In particular, the invention relates to a method of determining whether a subject has or is at risk of having nasal intestinal type adenocarcinoma (ITAC) comprising determining the expression level of CACNA1C in a sample wherein said expression level indicates whether the subject has or is at risk of having a nasal intestinal type adenocarcinoma (ITAC).

公开(公告)号：US20240269282A1

公开(公告)日：2024-08-15

申请号：US18290153

申请日：2022-05-10

申请人： Institut Curie ,  INSERM (Institut National de la Santé et de la Recherche Médicale)

发明人： Clotilde Thery ,  Mercedes Tkach

IPC分类号： A61K39/00 ,  A61K9/50 ,  A61P35/00 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0786

CPC分类号： A61K39/4614 ,  A61K9/5068 ,  A61K39/4631 ,  A61K39/4644 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/30 ,  C12N5/0645 ,  C12N2510/00

摘要： The invention relates to methods and pharmaceutical compositions for the treatment and diagnosis of cancer. The invention also relates to methods and pharmaceutical compositions for the treatment of inflammatory diseases and autoimmune diseases. The inventors investigate the role and specific contribution of extracellular vesicles (EVs) in cancer environment. The inventors demonstrate that CSF1-associated EVs induce macrophage signature associated with T cell infiltration and extended patient survival. The inventors demonstrate that via specific extracellular vesicles, these tumors promote pro-inflammatory macrophages correlated with better clinical outcome and a better prognosis in TNBC patients. In the present invention, the inventors provide in vitro evidences towards a direct role of CSF1-associated EVs as tools, alone or with other immuno-therapies, to promote anti-tumor immune responses. Thus, the present invention relates to CSF1-associated EVs, their use in the treatment and diagnosis of cancer, and their targeting in the treatment of inflammatory diseases and autoimmune diseases.

公开(公告)号：US20240229139A9

公开(公告)日：2024-07-11

申请号：US18546611

申请日：2022-02-16

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE ,  UNIVERSITÉ PARIS CITÉ ,  FONDATION IMAGINE ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)

发明人： Mickaël MENAGER ,  Julie TOUBIANA ,  Darragh DUFFY ,  Frédéric LAUCAT

IPC分类号： C12Q1/6883

CPC分类号： C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158

摘要： SARS-CoV-2 infection in children is generally milder than in adults, yet a proportion of cases result in hyperinflammatory conditions often including myocarditis. To better understand these cases, the inventors applied a multi-parametric approach to the study of blood cells of 56 children hospitalized with suspicion of SARS-CoV-2 infection. The most severe forms of MIS-C (multisystem inflammatory syndrome in children related to SARS-CoV-2), that resulted in myocarditis, were characterized by elevated levels of pro-angiogenesis cytokines and several chemokines. This phenotype was associated with TNF-α signaling, sustained NF-κB signaling in monocytic/dendritic cells, alongside increased HIF-1α and VEGF signaling. Single-cell transcriptomic analyses identified

公开(公告)号：US20240228987A1

公开(公告)日：2024-07-11

申请号：US18563078

申请日：2022-05-25

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE MONTPELLIER ,  UNIVERSITE DE PERPIGNAN VIA DOMITIA ,  ECOLE PRATIQUE DES HAUTES ETUDES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

发明人： Nicolas TRICAUD ,  Nicolas INGUIMBERT ,  Benoît GAUTIER

IPC分类号： C12N9/12 ,  A61K38/00 ,  A61P25/28

CPC分类号： C12N9/1205 ,  A61P25/28 ,  A61K38/00 ,  C12Y207/01001

摘要： The inventors previously demonstrated that mitochondrial VDAC1 directly induces Schwann cell demyelination via MAPK and c-jun activation after sciatic nerve injury and diabetic neuropathy and CMT1A. They found that reduction of mitochondrial calcium release by VDAC1 blocking strongly reduces the number of demyelinating Schwann cell in vivo and improve nerve conduction and neuromuscular activity in diabetic, Guillain-Barre syndrome and Charcot-Marie Tooth disease models. Herein, the inventors precisely map the binding region of the N-terminal HK-1 helix through an ala scan completed by a deletion study. Furthermore, they optimized the HK-derived peptide through stabilization of the helix by replacement of non-essential amino acids by the a-aminoisobutyric acid (Aib) known as a helix inducer. Additionally, they described an in-house cellular screening assay based on the ability of MJ to detach HK from VDAC that allows to determine the peptide potency. Overall, their data confirm that N-terminal HK derived peptides acting on VDAC are promising tools for the study of the demyelination process. Thus, the present invention refers to optimized HK-derived peptide and its use for treating peripheral demyelinating disease, myocardium diseases10 11, cancer12,13-15, diabetes14 14-16, lupus-like diseases17, non-alcoholic fatty liver disease24,25, chemoinduced neuropathy9 Alzheimer disease18 19, Parkinson disease20, Huntington disease21, ALS22,23 and more generally all neurodegenerative diseases linked to a protein aggregation28.

公开(公告)号：US12023420B2

公开(公告)日：2024-07-02

申请号：US15734027

申请日：2019-06-05

申请人： UNIVERSITÉ PAUL SABATIER TOULOUSE III ,  CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS ,  INSERM-INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE

发明人： Christophe Cognard ,  Olivier Eichwald ,  Cédric Garcia ,  Nofel Merbahi ,  Bernard Payrastre ,  Pierre Sie ,  Aurélie Tokarski ,  Ivan Vukasinovic ,  Mohammed Yousfi

IPC分类号： A61L31/10 ,  A61L31/02 ,  A61L31/04

CPC分类号： A61L31/10 ,  A61L31/022 ,  A61L31/047 ,  A61L2420/02

摘要： The present invention relates to a vascular stent, deployed or non-deployed, the surface of which is coated by a film comprising at least one protein, to a process for coating of the surface of a vascular stent with a film comprising at least one protein and to a device for carrying out the process according to the invention.

公开(公告)号：US20240190993A1

公开(公告)日：2024-06-13

申请号：US18555093

申请日：2022-04-13

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  OGD2 PHARMA ,  NANTES UNIVERSITÉ

发明人： Stéphane BIRKLE ,  Sarah VERMEULEN ,  Sophie FOUGERAY ,  Meriem BAHRI ,  Emilie MADURA ,  Jean-Marc LE DOUSSAL

IPC分类号： C07K16/30 ,  A61K31/203 ,  A61K39/00 ,  A61P35/00 ,  C07K14/55 ,  C07K16/28

CPC分类号： C07K16/3084 ,  A61K31/203 ,  A61P35/00 ,  C07K14/55 ,  C07K16/2803 ,  C07K16/2896 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565

摘要： The treatment of cancer and particularly the neuroblastoma, and a combination of an anti-O-acetylated disialoganglioside (OAcGD2) compound and an anti-SIRP-alpha/CD47 compound for treating a cancer in a subject in need thereof. The inventors hypothesized that CD47 expression would interfere with the contribution of macrophage to the therapeutic effect of anti-OAcGD2 mAbs. They found that NB cells up-regulate CD47 expression upon 8B6 mAb immunotherapy in vivo, allowing them to escape mAb 8B6-mediated ADP. Next, they demonstrate that an anti-SIRPα antibody that blocks the binding of CD47 to SIRPα enables macrophages to phagocyte anti-OAcGD2-opsonised CD47-expressing NB cells in vitro. As a result, the combination of CD47 blocking with the targeting of OAcGD2-positive NB cells greatly reduces tumor growth in syngeneic mice. These results suggest that the combination of anti-OAcGD2 mAbs with phagocytosis checkpoints inhibitors may represent a very effective regimen to achieve for lasting responses in a greater number of patients.

公开(公告)号：US20240159760A1

公开(公告)日：2024-05-16

申请号：US18550831

申请日：2022-03-16

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITÉ DE MONTPELLIER ,  CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER

发明人： Andrei TURTOI ,  François-Régis SOUCHE ,  Guillaume TOSATO ,  Jacques COLINGE

IPC分类号： G01N33/574

CPC分类号： G01N33/57438

摘要： The present invention relates to the diagnostics of pancreatic cancer. The inventors engineered a novel biomarker discovery approach, tailored for PDAC, which is all-patient inclusive, termed PanEXPEL. This approach offers access to PDAC clinical material before any treatment is applied. The method benefits from clinical biopsy, yet does not interfere with that diagnostic procedure. It can be integrated seamlessly into clinical routine, and is compatible with any type of OMICS profiling. PanEXPEL relies on the interstitial tissue fluid released from the lesion during diagnostic biopsy by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). This is the first technique that allows both clinicians and researchers to analyze identical material in the field of proteomics biomarker research. Here, they demonstrate the potential of PanEXPEL methodology by identifying a PDAC early detection signature through proteomics and subsequent statistical learning. Thus, the present invention relates to a method for diagnosing a pancreatic cancer in a subject in need thereof comprising determining in a sample obtained from the subject the expression levels of at least one biomarker selected from the group consisting of AGR2, ANXA2, ANXA3, ANXA4, CECAM6, CYP2S1, DMBT1, KRT7, KRT8, KRT17, KRT18, KRT19, MAL2, MYH14, 0LFM4, PIGR, SERPINB5, SERPINH1, and TIMP1.